Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00962195
Other study ID # P8604
Secondary ID
Status Completed
Phase N/A
First received August 18, 2009
Last updated April 13, 2010
Start date June 2009
Est. completion date December 2009

Study information

Verified date April 2010
Source TNO
Contact n/a
Is FDA regulated No
Health authority Netherlands: Dutch Health Care InspectorateNetherlands: Medical Ethics Review Committee (METC)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Purple Sweet Potato juice (PSP-juice) is a juice based on purple-fleshed sweet potato concentrate, containing a high level of anthocyanins. Purple-fleshed sweet potatoes have attracted attention to industry and scientists due to multiple physiological functions such as radical-scavenging, ACE-inhibitory and α-glucosidase inhibitory activities in vitro, and also hepato-protective, antihypertensive and antihyperglycemic effects in vivo. Previous studies in Japanese subjects showed potential beneficial effects of PSP beverages on liver function and blood pressure in volunteers with impaired hepatic function and/or hypertension.

The main objective of this study is to examine the effect of PSP-juice on liver enzymes and blood pressure. The secondary objective is to examine the effects of PSP-juice juice on insulin resistance.


Description:

Study design: The study is designed as a randomized, parallel, placebo-controlled, double-blind study.

Study population: 40 healthy adult female and/or male subjects, 40-70 yr old with a BMI 25-35 kg/m2, mildly elevated serum liver enzymes, and high normal blood pressure or mild hypertension.

Intervention: Daily oral intake of 3x 125 ml of PSP-juice or control juice for a period of 8 weeks.

Main study parameters/endpoints: Liver enzymes (GGT, ALAT, ASAT), blood pressure, glucose, insulin, haematology and serum clinical chemical profile


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2009
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

- Healthy as assessed by the: Health and Lifestyle Questionnaire, results of the pre study laboratory tests in blood

- Males/Females aged 40-70 years (boundaries included) at Day 01 of the study

- Body Mass Index (BMI) 25-35 (boundaries included) kg/m2

- Liver enzymes above reference values GGT = 45 IU/L (for males) and = 35 IU/L (for females), and/or ASAT = 45 IU/L (for males and females), and/or ALAT = 50 IU/L (for males) and = 40 IU/L (for females)

- Blood pressure (automated measurements at site): systolic blood pressure 130-159 mm Hg (boundaries included) and/or diastolic blood pressure 85-99 mm Hg (boundaries included)

- Voluntary participation

- Having given written informed consent

- Willing to comply with the study procedures

- Willing to give up blood/plasma donation during the study

- Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years

- Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.

Exclusion Criteria:

- Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study

- Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances

- Having a history of medical or surgical events that may significantly affect the study outcome

- Any concomitant medication, with the exception of occasional use of a paracetamol tablet, that may influence the outcome of the study (to be judged by the medical investigator)

- Food allergy/intolerance

- Alcohol consumption > 28 units/week for males and > 21 units/week for females

- Smoking > 10 cigarettes per day

- Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre study screening

- Reported slimming or medically prescribed diet

- Participation in night shift work

- Pregnant or lactating or wishing to become pregnant in the period of the study

- Personnel of TNO Quality of Life, their partner and their first and second degree relatives

- Not having a general practitioner

- Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
purple sweet potato (PSP)-juice
Daily oral intake of 3x 125 ml of PSP-juice or control juice

Locations

Country Name City State
Netherlands TNO Quality of Life Zeist Utrecht

Sponsors (2)

Lead Sponsor Collaborator
TNO Yakult Honsha Co., LTD

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary liver enzymes every 2 weeks during 8-weeks intervention No
Secondary blood pressure every 2 weeks during 8-weeks intervention No
Secondary insulin resistance every 2 weeks during 8-weeks intervention No
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4